Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Loading...
Embargo End Date
ICR Authors
Authors
Schmid, P
Abraham, J
Chan, S
Wheatley, D
Brunt, AM
Nemsadze, G
Baird, RD
Park, YH
Hall, PS
Perren, T
Stein, RC
Mangel, L
Ferrero, J-M
Phillips, M
Conibear, J
Cortes, J
Foxley, A
de Bruin, EC
McEwen, R
Stetson, D
Dougherty, B
Sarker, S-J
Prendergast, A
McLaughlin-Callan, M
Burgess, M
Lawrence, C
Cartwright, H
Mousa, K
Turner, NC
Abraham, J
Chan, S
Wheatley, D
Brunt, AM
Nemsadze, G
Baird, RD
Park, YH
Hall, PS
Perren, T
Stein, RC
Mangel, L
Ferrero, J-M
Phillips, M
Conibear, J
Cortes, J
Foxley, A
de Bruin, EC
McEwen, R
Stetson, D
Dougherty, B
Sarker, S-J
Prendergast, A
McLaughlin-Callan, M
Burgess, M
Lawrence, C
Cartwright, H
Mousa, K
Turner, NC
Document Type
Journal Article
Date
2020-02-10
Date Accepted
Abstract
PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC. PATIENTS AND METHODS: This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/AKT1/PTEN alterations, tumor response, and safety. RESULTS: Median PFS was 5.9 months with capivasertib plus paclitaxel and 4.2 months with placebo plus paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided P = .10]). Median OS was 19.1 months with capivasertib plus paclitaxel and 12.6 months with placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99; 2-sided P = .04). In patients with PIK3CA/AKT1/PTEN-altered tumors (n = 28), median PFS was 9.3 months with capivasertib plus paclitaxel and 3.7 months with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01). The most common grade ≥ 3 adverse events in those treated with capivasertib plus paclitaxel versus placebo plus paclitaxel, respectively, were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%). CONCLUSION: Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more pronounced in patients with PIK3CA/AKT1/PTEN-altered tumors. Capivasertib warrants further investigation for treatment of TNBC.
Citation
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 38 (5), pp. 423 - 433
Source Title
Publisher
AMER SOC CLINICAL ONCOLOGY
ISSN
0732-183X
eISSN
1527-7755
Collections
Research Team
Molecular Oncology